News and Events

UPDATE on July 23, 2019: 

PrimeVax Receives FDA's OK to Use Dengue Virus for Cancer Treatement

--- https://immuno-oncologynews.com/2019/07/23/fda-clears-primevax-to-launch-trials-on-virus-mediated-immunotherapy/

UPDATE on June 27, 2019: 

PrimeVax's third clinical trial is now live on clinicaltrials.gov.  

--- https://clinicaltrials.gov/ct2/show/NCT03990493

UPDATE on June 27, 2019: 

PrimeVax's second clinical trial is now live on clinicaltrials.gov.  

--- https://clinicaltrials.gov/ct2/show/NCT03989895

 

UPDATE on June 6, 2019: 

PrimeVax receives IND Permission from FDA for all 3 arms of the our clinical trials, including the dengue virus arms.

--- Globe Newswire press release

 

UPDATE on January 22, 2019: 

PrimeVax signs a worldwide exclusive license with the US Army for the use of the Army's dengue virus strain in cancer patients.  

--- PR Newswire press release

UPDATE on January 17, 2019: 

PrimeVax's first clinical trial is now live on clinicaltrials.gov.  

--- https://clinicaltrials.gov/ct2/show/NCT03803397

UPDATE on January 07, 2019: 

PrimeVax has recently been granted the Investigational New Drug (IND) permission to run our Phase I clinical trial. We are currently mobilizing our first trial site. 

--- PR Newswire press release

UPDATE on May 19, 2017:

PrimeVax will be speaking at the World Immunotherapy Congress in San Diego on May 23: 

---- Conference Agenda

UPDATE on February 21, 2017:

PrimeVax will be speaking at the Biocom Global Life Sciences Partnering Conference in San Diego on March 2: 

---- PR Newswire press release

In 2020, PrimeVax will make our way to the clinic: we intend to treat metastatic melanoma patients in a phase 1 human clinical trials at multiple trial sites. 

From 2017 - 2018, PrimeVax enabled our IND. 

From 2015 - 2016, PrimeVax conducted various pre-clinical experiments demonstrating mechanism of action and the potential to be translated in human clinical trials. 

For the latest details on our company's progress, please follow us on Twitter at @primevax.

© 2020 PrimeVax Immuno-Oncology

PrimeVax